MedTrace Logo

Hepatitis C Virus(HCV) Heart and Lung Study

NCT02858180 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2020-04-21

Study results available
· View outcomes & findings →

Summary

This is a multicenter study in Hepatitis C Virus (HCV) infected adult patients who also have advanced cardiac disease or advanced lung disease.

Conditions

  • Hepatitis C, Chronic
  • Heart Failure
  • Pulmonary Disease, Chronic Obstructive
  • Lung Diseases, Interstitial

Interventions

DRUG

Sofosbuvir/ledipasvir fixed dose combination(SOF/LDV FDC)

1 pill once daily of SOF/LDV FDC

Sponsors & Collaborators

Principal Investigators

  • Andrew Muir, MD · Duke University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-31
Primary Completion
2019-04-11
Completion
2019-07-04

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02858180 on ClinicalTrials.gov